SAB Biotherapeutics Inc

NASDAQ:SABS 4:00:00 PM EDT

3.39

+0.65 (+23.72%)

4:07:05 PM EDT: $3.26 -0.13 (-3.84%)

Market Cap (Intraday)	31.29M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.13 Million
Adjusted EPS	-$1.10

See more estimates

10-Day MA	$2.86
50-Day MA	$2.74
200-Day MA	$4.33

See more pivots

SAB Biotherapeutics Inc Stock, NASDAQ:SABS

777 West 41st Street, Suite 401, Miami Beach, Florida 33140

United States of America

Phone: +1.605.679.6980

Number of Employees: 57

http://www.sab.bio

Description

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.